STUDresearch · Peptide
Bonothyrk
Also known as
A-21 · A-21 parathyroid bioregulator · parathyroid cytomax · Bonotirk · Khavinson parathyroid complex · Bonothyrk peptide
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Oral capsules
Organ bioregulators
Aimed at parathyroid tissue in the writeups, but people still take it as a whole-body capsule.
What people say
Bonothyrk is sold for bone/calcium-support goals as an oral A-21 parathyroid-tissue peptide complex. It is distinct from thyroid product Thyreogen and approved anabolic PTH-receptor drugs.
Doses people talk about
Neither should be presented as an approved osteoporosis regimen or converted to teriparatide dosing.
How it may feel
No authentic first-person use diary appeared in the bounded community set. Product marketing and a delayed bone-density measurement cannot establish what someone feels after a capsule.
Broad community chart1–2 capsules, 1–2 times daily with meals, 10–30 days
An intact community-chart amount, not a validated regimen; other preserved drop and periodic-course descriptions remain distinct.
Conflicting seller page20 mg per two-capsule serving
Implies 10 mg per capsule in that line, but the page mixes a 20-capsule/10-day description, 60-capsule heading and one-month directions.
Developer brochure seriesTwo capsules twice daily for 30 days
Used in 20 climacteric women with 13 untreated controls; DXA was measured three months after the course ended, with no randomized, blinded or placebo-controlled design described.
Half-life & effect duration
- Half-life in the body
- Product half-lifeNo settled estimate
- Felt duration people report
- Felt durationNo consistent firsthand timeline reported
Cycles people discuss
Retail sources describe conflicting short-course directions and periodic repeats. A developer brochure used 30 days and measured DXA three months after that course ended; neither establishes a universal cycle.
Timing
Capsule charts place use with meals once or twice daily; brand-specific drop charts instead describe twice-daily sublingual use. Conflicting commercial directions do not establish one shared schedule or make capsule and drop routines equivalent.
Stacks
Cartalax / Sigumir: Cartilage neighbors.
Watch for
Calcium disorders: High or low calcium, kidney stones, known hyperparathyroidism — lab-and-clinic, not a peptide.
Tap a line for the full notes and source context.
Timing context & sources
Half-life in the body
No product-specific human bodily half-life was established in the reviewed sources.
Product labeling identifies capsule content, and a developer brochure describes a clinical series, but neither supplies analyte-resolved PK.
A tissue-derived mixture may contain multiple components; course length and measurement follow-up do not establish half-life.
- QI Supplements Bonothyrk product page (opens in a new tab)Product identity, title/description, ingredient and use sections: two capsules listed as 20 mg A-21; 20-capsule/10-day description conflicts with a 60-capsule ingredient heading and directions for 1–2 capsules 1–2 times daily with meals for one month.Commercial seller page with internally conflicting package/course text; the serving line implies 10 mg per capsule but does not resolve older label disagreement. Site-wide testimonials were not treated as product reports.
- Peptide bioregulators clinical researches brochure (opens in a new tab)Bonothyrk section, printed pages 9–11 (PDF indices 8–10): 33 climacteric women aged 47–56, 13 untreated controls and 20 receiving two capsules twice daily for 30 days; DXA measured three months after the course ended.Developer/vendor brochure, small nonrandomized untreated-control series, no placebo or blinding described, no identified peer-reviewed report and promotional interpretation.
Felt duration people report
The checked sources do not establish a felt-effect timeline.
The community item was promotional, and the developer brochure measured DXA three months after the 30-day course ended rather than subjective per-dose effects.
No authentic diary in the inspected set; this bounded absence is not proof that no account exists anywhere.
- Reddit promotional Bonothyrk post (opens in a new tab)Entire self-post: promotional product claims without a first-person use narrative or follow-up outcome.Commercial/promotional account, no verified use, no independent outcome and not representative of all community discussion.
- Peptide bioregulators clinical researches brochure (opens in a new tab)Bonothyrk section, printed pages 9–11 (PDF indices 8–10): 33 climacteric women aged 47–56, 13 untreated controls and 20 receiving two capsules twice daily for 30 days; DXA measured three months after the course ended.Developer/vendor brochure, small nonrandomized untreated-control series, no placebo or blinding described, no identified peer-reviewed report and promotional interpretation.
What people say
- Calcium / bone-wellness pitch: Seller pages talk PTH-axis “normalization,” cramps, vitamin D absorption stories. Uncontrolled. forum
- Hyper- and hypo-parathyroid marketing: Some product pages claim both directions. That is a red-flag overreach versus how PTH drugs actually work. forum
- Kit halo: Lands next to Cartalax / Sigumir / Gotratix in connective-tissue calendars. forum
- What logs don’t show: iPTH, calcium, phosphate, DXA before/after in public threads. forum
- BMD developer series: A brochure describes 33 climacteric women aged 47–56 with low BMD: 20 received Bonothyrk and 13 were untreated controls, with DXA measured three months after the 30-day course ended. No randomization, placebo, blinding or peer-reviewed report is identified; this is not Forteo or anabolic PTH evidence. trial
Doses people talk about
- Broad chart: 1–2 capsules, 1–2 times daily with meals, 10–30 days. forum
- Intensive then 10-day packs: 2 caps daily × 30 days, then 10-day courses every 2–3 months. forum
- Sublingual drops: Secondary pages mention ~10 drops under the tongue twice daily — brand-specific. forum
- Do not copy teriparatide micrograms onto this complex. forum
- Checked seller page: A two-capsule serving is listed as 20 mg A-21, implying 10 mg per capsule in that line. The same page mixes a 20-capsule/10-day description with a 60-capsule ingredient heading and directions for 1–2 capsules 1–2 times daily with meals for one month. Older label-disagreement discussion remains unresolved; these are commercial descriptions, not a validated regimen. forum
- Framing: Cytomax charts — not anabolic PTH dosing. forum
- Developer brochure series: 2 capsules twice daily for 30 days in 20 climacteric women aged 47–56 with low BMD, compared with 13 untreated controls; DXA was measured three months after the course ended. No randomization, placebo or blinding is described; this is not anabolic PTH/Forteo dosing. trial
How it may feel
- First-person evidence: No authentic Bonothyrk user diary was found in the bounded community set; the inspected Reddit item was promotional and did not report personal use. forum
- End of 30 days: Retail and cited-series checkpoint. forum
- 3–6 month re-runs: Same A-series calendar. forum
- If cramps or stones are the worry: That’s labs and a clinician, not another 10-day pack. forum
- No reliable felt timeline: Product pages and a promotional post do not establish what a user notices or when; the developer brochure measured bone density months later, not acute sensation. forum
Cycles people discuss
- 10–30 day courses. forum
- Repeat every 3–6 months in retail language; some say max ~5 intensives/year with gaps. forum
- Not daily forever. forum
Timing
- With meals: Chart default. forum
- Not Forteo’s once-daily anabolic window. forum
- Course logic: Tissue-complex / gene-expression story. forum
- PK honesty: No public human PK for A-21. trial
More on what it is
- What it is: Natural peptide complex from parathyroid tissue, Khavinson cytomax A-21. Also spelled Bonotirk on some bottles. Not PTH 1-34. Not a calcium pill. forum
- Why people search it: Bone-density / calcium-balance lists, and X users who name-drop Sigumir, Cartalax, Gotratix, Thyreogen, Bonothyrk together and admit they can’t find much. forum
- Not Thyreogen: Thyreogen is thyroid. Bonothyrk is parathyroid. Different glands, both “thyr-” in the catalog. forum
- Forum diaries: Almost none. This is catalog-complete, not loud. forum
- Not Teriparatide / Abaloparatide: Those are anabolic PTH-receptor drugs with real BMD trials. This is a tissue-complex capsule. trial
- Evidence honesty: Influencer pages cite a small originating-group climacteric/osteoporosis-risk series (women ~47–56, 2 caps BID × 30 days, BMD talk). Not a modern DXA RCT you can pull easily in English. trial
Stacks
- Cartalax / Sigumir: Cartilage neighbors. forum
- Thyreogen: Easy name-mix; different gland. forum
- Vitamin D / calcium: People already on bone stacks add this as a “gland” layer. Confounded. forum
- Not a skip-the-DXA stack. forum
Storage notes
- Capsules: Dry storage per the bottle. forum
- No mix instructions here: STUDresearch does not list reconstitution charts. forum
Watch for
- Fine print: Intolerance, pregnancy, lactation. forum
- GI: Capsule. forum
- Animal-tissue complex. forum
- Calcium disorders: High or low calcium, kidney stones, known hyperparathyroidism — lab-and-clinic, not a peptide. forum
- Marketing both hyper- and hypo- is a caution, not a feature. forum
- Don’t confuse with anabolic PTH shots. trial
- Regulatory: Not an approved osteoporosis drug. trial
- Research-only framing: Discussion of community practice — not a recommendation to use in humans or animals. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.